GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Barinthus Biotherapeutics PLC (NAS:BRNS) » Definitions » Pre-Tax Income

BRNS (Barinthus Biotherapeutics) Pre-Tax Income : $-61.23 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Barinthus Biotherapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Barinthus Biotherapeutics's pretax income for the three months ended in Dec. 2024 was $-20.59 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-61.23 Mil. Barinthus Biotherapeutics's pretax margin was %.

During the past 6 years, Barinthus Biotherapeutics's highest Pretax Margin was 1.90%. The lowest was -19082.09%. And the median was -409.03%.


Barinthus Biotherapeutics Pre-Tax Income Historical Data

The historical data trend for Barinthus Biotherapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Barinthus Biotherapeutics Pre-Tax Income Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pre-Tax Income
Get a 7-Day Free Trial -17.84 -51.14 0.85 -76.52 -61.23

Barinthus Biotherapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.11 -15.56 -16.95 -8.13 -20.59

Competitive Comparison of Barinthus Biotherapeutics's Pre-Tax Income

For the Biotechnology subindustry, Barinthus Biotherapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Barinthus Biotherapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's Pre-Tax Income falls into.


;
;

Barinthus Biotherapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Barinthus Biotherapeutics's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-51.778+-12.074+-0.053+2.678+0
=-61.23

Barinthus Biotherapeutics's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-9.093+-12.12+-0.012+0.637+0
=-20.59

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-61.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Barinthus Biotherapeutics  (NAS:BRNS) Pre-Tax Income Explanation

Barinthus Biotherapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-20.588/0
=%

During the past 6 years, Barinthus Biotherapeutics's highest Pretax Margin was 1.90%. The lowest was -19082.09%. And the median was -409.03%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Barinthus Biotherapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Barinthus Biotherapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Barinthus Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, GBR, OX11 0DF
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
Executives
Joseph Scheeren director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Robin Wright director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
William Enright director, officer: Chief Executive Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Nadege Pelletier officer: Chief Scientific Officer C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Gemma Brown officer: Chief Financial Officer VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Graham Griffiths officer: Chief Business Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Christopher Ellis officer: Chief Operating Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Oxford Science Enterprises Plc 10 percent owner 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Pierre A. Morgon director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Margaret Marshall officer: Chief Medical Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Thomas George Evans officer: Chief Scientific Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Alex Hammacher director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Georgy Egorov officer: Chief Financial Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE

Barinthus Biotherapeutics Headlines

From GuruFocus

Vaccitech to Present at Upcoming November Investors Conferences

By Value_Insider Value_Insider 11-09-2022